Ketorolac Pediatric Dose — Analgesics
Ketorolac is a parenteral nonsteroidal anti-inflammatory drug (NSAID) that exerts its analgesic and anti-inflammatory effects through non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. It is indicated in pediatric patients for the short-term management of moderate to severe acute pain when an opioid-sparing or non-opioid intravenous analgesic strategy is appropriate. Common clinical applications include postoperative pain, renal colic, sickle cell vaso-occlusive crisis, and migraine management.
Pediatric Dosing
- Dose: 0.5 mg/kg IV every 6 hours
- Maximum single dose: 30 mg IV per dose
- Maximum duration: 5 days (combined IV and oral use)
- Age restriction: Not for use in patients younger than 2 months of age
For a 20 kg child: 20 × 0.5 mg/kg = 10 mg IV every 6 hours. For a 70 kg adolescent: 70 × 0.5 mg/kg = 35 mg — however, the dose is capped at 30 mg IV per dose regardless of weight. Consult institutional protocol for dose adjustments in patients with renal impairment or hypovolemia.
Indications and Clinical Context
Ketorolac is used for short-term management of moderate to severe acute pain in pediatric patients who require parenteral analgesia. As an NSAID, it provides effective pain control without the respiratory depression associated with opioids, making it a valuable component of multimodal analgesia strategies in postoperative and emergency department settings. It is particularly useful in conditions where inflammation contributes to pain, such as musculoskeletal injuries, renal colic, and acute headache syndromes.
The strict 5-day maximum duration is a critical safety constraint intended to minimize the risk of serious adverse effects, including gastrointestinal bleeding and nephrotoxicity. Clinicians should reassess the need for continued analgesia daily and transition to oral agents or alternative analgesics as soon as clinically appropriate.
Administration and Monitoring
Ketorolac should be administered intravenously as a slow IV push over a minimum of 15 seconds, though institutional protocols may recommend infusion over 1–5 minutes. Ensure adequate hydration prior to and during therapy, as hypovolemia significantly increases the risk of renal toxicity. The drug is contraindicated in patients with known hypersensitivity to NSAIDs or aspirin, active peptic ulcer disease, significant renal impairment, or coagulopathy.
- Monitor renal function (BUN, creatinine) with prolonged use or in at-risk patients
- Assess for signs of gastrointestinal bleeding or ulceration
- Use with caution in patients with asthma, as NSAID-induced bronchospasm may occur
- Avoid concurrent use with other NSAIDs or nephrotoxic agents
- Do not exceed 5 cumulative days of ketorolac therapy (IV and oral combined)
- Not for use in neonates or infants younger than 2 months of age
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.